Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Capital Expenditures for 9 consecutive years, with $713000.0 as the latest value for Q1 2026.

  • For Q1 2026, Capital Expenditures rose 18.05% year-over-year to $713000.0; the TTM value through Mar 2026 reached $2.5 million, up 34.59%, while the annual FY2025 figure was $2.4 million, 90.28% up from the prior year.
  • Capital Expenditures hit $713000.0 in Q1 2026 for Bicycle Therapeutics, up from $574000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $9.8 million in Q2 2022 and bottomed at $12000.0 in Q1 2024.
  • Average Capital Expenditures over 5 years is $1.5 million, with a median of $574000.0 recorded in 2025.
  • Year-over-year, Capital Expenditures soared 5630.41% in 2022 and then crashed 99.43% in 2024.
  • Bicycle Therapeutics' Capital Expenditures stood at $1.4 million in 2022, then plummeted by 96.48% to $51000.0 in 2023, then skyrocketed by 621.57% to $368000.0 in 2024, then soared by 55.98% to $574000.0 in 2025, then increased by 24.22% to $713000.0 in 2026.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $713000.0, $574000.0, and $674000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.